Investigation of immunogenic effect of the BCG priming and Ag85A- GM-CSF boosting in Balb/c mice model

Dou, Jun; Tang, Qiulin; Yu, Faquan; Yang, Haitao; Zhao, Fengshu; Xu, Weiguo; Wang, Jing; Hu, Weihua; Hu, Kai; Liou, Chunsheng; He, Xiang; Wang, Yaqing

doi:10.1016/j.imbio.2009.04.002

Cited by 23 publications

(13 citation statements)

References 34 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several vaccines strategies are currently being developed and many groups have studied the use of DNA vaccines using the intramuscular pathway (Dou et al, 2010; Yuan et al, 2012). However, this pathway requires very high quantities of the DNA vaccine (in the range of μg of DNA) and also an invasive pathway, which is not considered very effective in inducing the mucosal immune response, therefore reducing its capacity to prevent against infection at mucosal surfaces (Neutra and Kozlowski, 2006; Lycke, 2012).…”

Section: Discussionmentioning

confidence: 99%

Recombinant Invasive Lactococcus lactis Carrying a DNA Vaccine Coding the Ag85A Antigen Increases INF-γ, IL-6, and TNF-α Cytokines after Intranasal Immunization

et al. 2017

View full text Add to dashboard Cite

Tuberculosis (TB) remains a major threat throughout the world and in 2015 it caused the death of 1.4 million people. The Bacillus Calmette-Guérin is the only existing vaccine against this ancient disease; however, it does not provide complete protection in adults. New vaccines against TB are eminently a global priority. The use of bacteria as vehicles for delivery of vaccine plasmids is a promising vaccination strategy. In this study, we evaluated the use of, an engineered invasive Lactococcus lactis (expressing Fibronectin-Binding Protein A from Staphylococcus aureus) for the delivery of DNA plasmid to host cells, especially to the mucosal site as a new DNA vaccine against tuberculosis. One of the major antigens documented that offers protective responses against Mycobacterium tuberculosis is the Ag85A. L. lactis FnBPA+ (pValac:Ag85A) which was obtained and used for intranasal immunization of C57BL/6 mice and the immune response profile was evaluated. In this study we observed that this strain was able to produce significant increases in the amount of pro-inflammatory cytokines (IFN-γ, TNF-α, and IL-6) in the stimulated spleen cell supernatants, showing a systemic T helper 1 (Th1) cell response. Antibody production (IgG and sIgA anti-Ag85A) was also significantly increased in bronchoalveolar lavage, as well as in the serum of mice. In summary, these findings open new perspectives in the area of mucosal DNA vaccine, against specific pathogens using a Lactic Acid Bacteria such as L. lactis.

show abstract

Section: Discussionmentioning

confidence: 99%

Recombinant Invasive Lactococcus lactis Carrying a DNA Vaccine Coding the Ag85A Antigen Increases INF-γ, IL-6, and TNF-α Cytokines after Intranasal Immunization

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The serum samples were tested in triplicate starting at a dilution of 1:100. The cutoff value used was 0.1 U/ml for IFN-γ and IL-4, corresponding to 3 standard deviations (SDs) above the mean values found in the standard negative control cultures [41]. …”

Section: Methodsmentioning

confidence: 99%

Topical Administration Is a Promising Inoculating Route versus Intramuscular Inoculation for the Nanoparticle-Carried DNA Vaccine to Prevent Corneal Infections

Malla²,

Zhai³

et al. 2015

Ophthalmic Res

Self Cite

View full text Add to dashboard Cite

Purpose: To evaluate the comparative effect of topical versus intramuscular administration of nanoparticle-carried DNA vaccine in preventing corneal herpes simplex virus type 1 (HSV-1) infection. Methods: Nanoparticle [polyethylenimine (PEI)-Fe₃O₄]-carried DNA vaccine (PEI-Fe₃O₄-pRSC-gD-IL-21) or DNA vaccine (pRSC-gD-IL-21) alone were topically versus intramuscularly inoculated into one eye each of mice on days 0, 14 and 28. Three weeks after the final immunization, the specific immune responses and clinical degrees of primary herpes simplex keratitis were evaluated. Results: Topical inoculation of nanoparticle-carried DNA vaccine induced mice to generate similar levels of specific HSV-1-neutralizing antibody, IFN-γ and IL-4 in serum and specific killing (cytotoxicity) and proliferative activities of the splenic lymphocytes, but a significantly higher level of secretory IgA in tears compared to those of intramuscular inoculation. More importantly, the mice inoculated topically showed a significantly decreased herpes simplex keratitis severity than the mice inoculated intramuscularly after HSV-1 challenge on the corneas of the mice. Conclusions: Topical inoculation of nanoparticle-carried DNA vaccine elicits a stronger specific local immune response and more effectively inhibits herpes simplex keratitis as compared to intramuscular inoculation in an HSV-1 ocular challenge mouse model. Thus, topical administration may be a promising inoculating route for the nanoparticle-carried DNA vaccine to prevent corneal infections.

show abstract

“…37 Enhanced responses to encoded antigens have been obtained by additionally encoding cytokines, such as interleukin 21 (IL-21), with Ag85A 38 or Ag85A/ESAT6, 39 and GM-CSF with Ag85A. 40 Inclusion of DNA expressing IL-12 enhanced prime/boost responses to BCG and to plasmids expressing Ag85A and ESAT6. 41 ESAT6 DNA priming and protein boosting has also been shown to give enhanced Th1 responses.…”

Section: Tb Immunitymentioning

confidence: 99%

Tuberculosis vaccine research in China

Lowrie

2012

Emerging Microbes & Infections

View full text Add to dashboard Cite

It is now privately acknowledged that there may be little if any perceptible impact of the national Bacille Calmette–Guerin (BCG) vaccination program on disease prevalence, despite the extensive coverage of the newborn infant population and likely benefit in the early years of life. A better preventive vaccine than BCG is now being sought by Chinese researchers. Urgency has been added to the control problem by the emergence of multidrug-resistant tuberculosis (TB). Furthermore, expensive second-line drugs seem unlikely to be made available by the government to treat drug-resistant cases, so attention in addition has turned to the potential of immunotherapy as an adjunct to chemotherapy. Research trends are summarized here.

show abstract

Investigation of immunogenic effect of the BCG priming and Ag85A- GM-CSF boosting in Balb/c mice model

Cited by 23 publications

References 34 publications

Recombinant Invasive Lactococcus lactis Carrying a DNA Vaccine Coding the Ag85A Antigen Increases INF-γ, IL-6, and TNF-α Cytokines after Intranasal Immunization

Recombinant Invasive Lactococcus lactis Carrying a DNA Vaccine Coding the Ag85A Antigen Increases INF-γ, IL-6, and TNF-α Cytokines after Intranasal Immunization

Topical Administration Is a Promising Inoculating Route versus Intramuscular Inoculation for the Nanoparticle-Carried DNA Vaccine to Prevent Corneal Infections

Tuberculosis vaccine research in China

Contact Info

Product

Resources

About